Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement Tango Therapeutics Inc. (
NASDAQ:TNGX ) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.
Wondering what's happening in today's pre-market session? Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.
Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus.
What's going on in today's session Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Which stocks are experiencing notable movement on Monday? Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
